{"success":true,"data":{"pressRelease":{"id":"159302","rtpr_id":"nGNE7fHBcv-20261002","ticker":"TEVA","exchange":"","all_tickers":["TEVA"],"title":"Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome","author":"Globe Newswire","published_at":"2026-10-02T12:00:00.114Z","article_body":"* Based on a post hoc analysis, a majority of participants (~70%) experienced\nclinically meaningful tic reduction within 8 weeks of starting ecopipam\n* An interim 18-month analysis of an ongoing open-label extension study\ndemonstrated a mean reduction in tic severity scores (45.6%) with no new\nsafety signals observed\n* Additional analyses found that common concurrent psychiatric conditions did\nnot negatively impact ecopipam’s efficacy or safety, adding to the growing\nbody of evidence supporting ecopipam’s application currently under FDA\nPriority Review\nPARSIPPANY, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a\nU.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA),\ntoday announced new data for ecopipam, a first-in-class investigational\nselective D1 (dopamine) receptor antagonist for the treatment of pediatric\npatients with Tourette syndrome. Presented at the International Congress of\nParkinson’s Disease and Movement Disorders (MDS) in Seoul, South Korea\n(October 4–8, 2026), the data include a post hoc analysis of safety and\nefficacy during the initial 8 weeks of treatment with ecopipam, long-term\nefficacy and safety from an interim analysis of an ongoing open-label\nextension (OLE) study, post hoc subgroup analyses and preclinical receptor\nselectivity findings.\n\n“Tourette syndrome is a complex neurodevelopmental disorder that presents\nsignificant daily challenges for children and their families,” said Eric\nHughes, M.D., Ph.D., Executive Vice President, Global R&D and Chief Medical\nOfficer of Teva. “These promising new data for ecopipam reinforce our\nconfidence in its potential in pediatric Tourette syndrome care. If approved,\necopipam would be the first new therapy for Tourette syndrome in more than 10\nyears and the first with a novel mechanism of action in more than 50 years.”\n\nKey Findings from Studies Include:\n* Tic Severity Reduction Observed Within Two Months of Treatment: In a pooled\npost hoc analysis of 292 patients across Phase 2b and Phase 3 trials, a\nclinically meaningful improvement in the Yale Global Tic Severity Scale Total\nTic Score (YGTSS-TTS) (score ≥25%) was observed in 69.8% of participants\nwithin the first eight weeks of treatment with ecopipam. The most commonly\nreported adverse events (AEs) were somnolence and headache, and the most\ncommonly reported cross-trial AEs were most often observed within the first\neight weeks of ecopipam exposure.\n\n\n* Clinically Meaningful Reduction in Tic Severity Sustained >1 year: An\ninterim analysis of an ongoing 36-month OLE study included patients who\ncompleted the phase 3 study and the phase 2b OLE study receiving ecopipam\ntitrated over 3-4 weeks then maintained at a target dose for up to 36 months.\nThe study evaluated 118 children, adolescents and adults with Tourette\nsyndrome who received at least one dose of ecopipam (median treatment exposure\nof 14.9 months). Ecopipam maintained clinically meaningful tic suppression\nthrough 18 months according to the YGTSS-TTS. The most commonly reported AEs\nwere nasopharyngitis, upper respiratory tract infection, anxiety, diarrhea,\ninfluenza, pyrexia and insomnia. \n\n\n* Co-Occurring Psychiatric Conditions Did Not Impact Efficacy or Safety of\nEcopipam: A post hoc analysis evaluated 216 participants (aged ≥6 years)\nfrom the Phase 3 trial, comparing outcomes between those with (n=129) and\nwithout (n=87) common co-occurring psychiatric conditions, including ADHD,\nOCD, anxiety and depression. During the 12-week open-label period, the\npresence of co-occurring conditions did not negatively impact reductions in\ntic severity, with mean YGTSS-TTS score reductions consistent across\nparticipants with ≥1 co-occurring conditions and those without. Overall\nsafety and tolerability profiles were similarly consistent between both\ngroups.\n“Many children with Tourette syndrome do not receive treatment, and among\nthose who do, treatment is often discontinued within a year because symptoms\nremain inadequately controlled or side effects become difficult to\ntolerate,” said Donald L. Gilbert, M.D., M.S., Pediatric Movement Disorders\nand Tourette Syndrome Specialist, Division of Neurology, Cincinnati\nChildren’s Hospital Medical Center. “Children living with Tourette\nsyndrome urgently need treatment options that work rapidly, remain effective\nover time and have a demonstrated tolerability profile. These findings are\nencouraging because they suggest that, if approved, ecopipam may offer\npatients and families a meaningful new option.”\n\nAbout Tourette Syndrome\nTourette syndrome is a chronic neuro-developmental disorder characterized by\ninvoluntary motor and vocal tics beginning in childhood, often between 5 and\n10 years of age.(2) For people living with Tourette syndrome, symptoms can be\nfrequent, visible and disruptive, affecting everyday life.(2)\n\nAbout Ecopipam and Its Clinical Program\nEcopipam is a first-in-class investigational therapy designed to block\ndopamine signaling at the D1 receptor. D1 receptor hypersensitivity may\ncontribute to repetitive and compulsive behaviors associated with Tourette\nsyndrome.\n\nEcopipam was granted Priority Review by the FDA with Orphan Drug designation\nfor the treatment of pediatric patients with Tourette syndrome. Orphan Drug\ndesignation is reserved for patient populations of 200,000 or fewer.\n\nThe D1AMOND Phase 2b Trial was a 12-week randomized, double-blind,\nplacebo-controlled trial that studied 153 pediatric participants across 68\nsites in North America and Europe. The primary efficacy endpoint was the\nchange in the YGTSS-TTS, i.e., sum of the motor and vocal tic scores, from\nbaseline to end of therapy.(3) The associated Phase 2b open-label extension\nenrolled 121 pediatric subjects from the Phase 2b trial and followed them for\nup to 12 months’ duration to evaluate the long-term safety and tolerability\nof ecopipam.(4) The subsequent D1AMOND Phase 3 Trial was a double-blind,\nplacebo-controlled, randomized withdrawal trial enrolling a total of 216\npediatric and adult participants into an open-label stabilization period and\nrandomizing 104 participants (90 pediatric, 14 adult) across 77 sites in North\nAmerica and Europe. The objective of this study was to evaluate the\nmaintenance of efficacy of ecopipam in pediatric and adult responders\nutilizing the YGTSS-TTS change from randomization or increased\nTourette-specific care to determine relapse.(5) While this Phase 3 trial\nincluded adult participants, the accepted NDA and resulting indication sought\nby Teva are exclusively for pediatric patients.\n\nAbout Teva\nTeva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into\na leading innovative biopharmaceutical company, enabled by a world-class\ngenerics business. For over 120 years, Teva’s commitment to bettering health\nhas never wavered. From innovating in the fields of neuroscience and\nimmunology to providing complex generic medicines, biosimilars and pharmacy\nbrands worldwide, Teva is dedicated to addressing patients’ needs, now and\nin the future. At Teva, We Are All In For Better Health. To learn more about\nhow, visit www.tevapharm.com.\n\nCautionary Note Regarding Forward-Looking Statements\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995, which are based on\nmanagement’s current beliefs and expectations and are subject to substantial\nrisks and uncertainties, both known and unknown, that could cause Teva’s\nfuture results, performance or achievements to differ significantly from that\nexpressed or implied by such forward-looking statements. All statements other\nthan statements of historical fact are, or may be deemed to be,\nforward-looking statements. In some cases, you can identify these\nforward-looking statements by the use of words such as “should,”\n“expect,” “anticipate,” “developing,” “target,” “may,”\n“expand,” “intend,” “plan,” “believe” and other words and\nterms of similar meaning and expression in connection with any discussion of\nfuture performance. Important factors that could cause or contribute to such\ndifferences include risks and uncertainties relating to: our ability to\nsuccessfully develop, obtain regulatory approval for and commercialize\necopipam; our ability to successfully compete in the marketplace including our\nability to develop and commercialize ecopipam for the treatment of pediatric\npatients with Tourette syndrome; our ability to successfully execute on our\nPivot to Growth strategy, including to expand our innovative and biosimilar\nmedicines pipeline and to profitably commercialize our innovative medicines\nand biosimilar portfolio, whether organically or through business development,\nand to execute on our organizational transformation and to achieve expected\ncost savings; our significant indebtedness, which may limit our ability to\nincur additional indebtedness, engage in additional transactions or make new\ninvestments; and other factors discussed in this press release, in our\nQuarterly Report on Form 10-Q for the second quarter of 2026 and in our Annual\nReport on Form 10-K for the year ended December 31, 2025, including in the\nsections captioned “Risk Factors” and “Cautionary Note Regarding Forward\nLooking Statements.” Forward-looking statements speak only as of the date on\nwhich they are made, and we assume no obligation to update or revise any\nforward-looking statements or other information contained herein, whether as a\nresult of new information, future events or otherwise. You are cautioned not\nto put undue reliance on these forward-looking statements.\n\nReferences:\n1. U.S. Food and Drug Administration (FDA) Approval Records: Haloperidol\n(1969), Pimozide (1984), Aripiprazole (2014); Pringsheim, T., et al. (2019).\nThe pharmacological management of tic disorders: an updated practice\nguideline. Neurology.\n2. CDC | Tourette Syndrome | Data and Statistics on Tourette Syndrome, 2024;\nMayo Clinic | Tourette Syndrome – Diagnosis and treatment, 2025.\n3. Gilbert DL, Dubow JS, Cunniff TM, et al. Ecopipam for Tourette Syndrome: A\nRandomized Trial. Pediatrics. 2023;151(2):e2022059574.\ndoi:10.1542/peds.2022-059574\n4. Gilbert DL, Kim DJB, Miller MM, et al. Safety and Effect of 12-Month\nEcopipam Treatment in Pediatric Patients with Tourette Syndrome. Mov Disord\nClin Pract. 2025;12(8):1157-1166. doi:10.1002/mdc3.70091.\n5. Gilbert DL, Atkinson SD, Kim DJB, et al. Efficacy and Safety of Ecopipam\nfor Tourette Syndrome: A Phase 3 Randomized Clinical Trial. JAMA Neurol.\n2026;83(7):645–653. doi:10.1001/jamaneurol.2026.1431\nTeva Media Inquiries:\nTevaCommunicationsNorthAmerica@tevapharm.com\n\nTeva Investor Relations Inquiries:\nTevaIR@Tevapharm.com","article_body_html":"","raw_payload":{"data":{"id":"nGNE7fHBcv-20261002","title":"Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome","author":"Globe Newswire","ticker":"TEVA","created":"2026-10-02T12:00:00.114Z","tickers":["TEVA"],"exchange":"","article_body":"* Based on a post hoc analysis, a majority of participants (~70%) experienced\nclinically meaningful tic reduction within 8 weeks of starting ecopipam\n* An interim 18-month analysis of an ongoing open-label extension study\ndemonstrated a mean reduction in tic severity scores (45.6%) with no new\nsafety signals observed\n* Additional analyses found that common concurrent psychiatric conditions did\nnot negatively impact ecopipam’s efficacy or safety, adding to the growing\nbody of evidence supporting ecopipam’s application currently under FDA\nPriority Review\nPARSIPPANY, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a\nU.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA),\ntoday announced new data for ecopipam, a first-in-class investigational\nselective D1 (dopamine) receptor antagonist for the treatment of pediatric\npatients with Tourette syndrome. Presented at the International Congress of\nParkinson’s Disease and Movement Disorders (MDS) in Seoul, South Korea\n(October 4–8, 2026), the data include a post hoc analysis of safety and\nefficacy during the initial 8 weeks of treatment with ecopipam, long-term\nefficacy and safety from an interim analysis of an ongoing open-label\nextension (OLE) study, post hoc subgroup analyses and preclinical receptor\nselectivity findings.\n\n“Tourette syndrome is a complex neurodevelopmental disorder that presents\nsignificant daily challenges for children and their families,” said Eric\nHughes, M.D., Ph.D., Executive Vice President, Global R&D and Chief Medical\nOfficer of Teva. “These promising new data for ecopipam reinforce our\nconfidence in its potential in pediatric Tourette syndrome care. If approved,\necopipam would be the first new therapy for Tourette syndrome in more than 10\nyears and the first with a novel mechanism of action in more than 50 years.”\n\nKey Findings from Studies Include:\n* Tic Severity Reduction Observed Within Two Months of Treatment: In a pooled\npost hoc analysis of 292 patients across Phase 2b and Phase 3 trials, a\nclinically meaningful improvement in the Yale Global Tic Severity Scale Total\nTic Score (YGTSS-TTS) (score ≥25%) was observed in 69.8% of participants\nwithin the first eight weeks of treatment with ecopipam. The most commonly\nreported adverse events (AEs) were somnolence and headache, and the most\ncommonly reported cross-trial AEs were most often observed within the first\neight weeks of ecopipam exposure.\n\n\n* Clinically Meaningful Reduction in Tic Severity Sustained >1 year: An\ninterim analysis of an ongoing 36-month OLE study included patients who\ncompleted the phase 3 study and the phase 2b OLE study receiving ecopipam\ntitrated over 3-4 weeks then maintained at a target dose for up to 36 months.\nThe study evaluated 118 children, adolescents and adults with Tourette\nsyndrome who received at least one dose of ecopipam (median treatment exposure\nof 14.9 months). Ecopipam maintained clinically meaningful tic suppression\nthrough 18 months according to the YGTSS-TTS. The most commonly reported AEs\nwere nasopharyngitis, upper respiratory tract infection, anxiety, diarrhea,\ninfluenza, pyrexia and insomnia. \n\n\n* Co-Occurring Psychiatric Conditions Did Not Impact Efficacy or Safety of\nEcopipam: A post hoc analysis evaluated 216 participants (aged ≥6 years)\nfrom the Phase 3 trial, comparing outcomes between those with (n=129) and\nwithout (n=87) common co-occurring psychiatric conditions, including ADHD,\nOCD, anxiety and depression. During the 12-week open-label period, the\npresence of co-occurring conditions did not negatively impact reductions in\ntic severity, with mean YGTSS-TTS score reductions consistent across\nparticipants with ≥1 co-occurring conditions and those without. Overall\nsafety and tolerability profiles were similarly consistent between both\ngroups.\n“Many children with Tourette syndrome do not receive treatment, and among\nthose who do, treatment is often discontinued within a year because symptoms\nremain inadequately controlled or side effects become difficult to\ntolerate,” said Donald L. Gilbert, M.D., M.S., Pediatric Movement Disorders\nand Tourette Syndrome Specialist, Division of Neurology, Cincinnati\nChildren’s Hospital Medical Center. “Children living with Tourette\nsyndrome urgently need treatment options that work rapidly, remain effective\nover time and have a demonstrated tolerability profile. These findings are\nencouraging because they suggest that, if approved, ecopipam may offer\npatients and families a meaningful new option.”\n\nAbout Tourette Syndrome\nTourette syndrome is a chronic neuro-developmental disorder characterized by\ninvoluntary motor and vocal tics beginning in childhood, often between 5 and\n10 years of age.(2) For people living with Tourette syndrome, symptoms can be\nfrequent, visible and disruptive, affecting everyday life.(2)\n\nAbout Ecopipam and Its Clinical Program\nEcopipam is a first-in-class investigational therapy designed to block\ndopamine signaling at the D1 receptor. D1 receptor hypersensitivity may\ncontribute to repetitive and compulsive behaviors associated with Tourette\nsyndrome.\n\nEcopipam was granted Priority Review by the FDA with Orphan Drug designation\nfor the treatment of pediatric patients with Tourette syndrome. Orphan Drug\ndesignation is reserved for patient populations of 200,000 or fewer.\n\nThe D1AMOND Phase 2b Trial was a 12-week randomized, double-blind,\nplacebo-controlled trial that studied 153 pediatric participants across 68\nsites in North America and Europe. The primary efficacy endpoint was the\nchange in the YGTSS-TTS, i.e., sum of the motor and vocal tic scores, from\nbaseline to end of therapy.(3) The associated Phase 2b open-label extension\nenrolled 121 pediatric subjects from the Phase 2b trial and followed them for\nup to 12 months’ duration to evaluate the long-term safety and tolerability\nof ecopipam.(4) The subsequent D1AMOND Phase 3 Trial was a double-blind,\nplacebo-controlled, randomized withdrawal trial enrolling a total of 216\npediatric and adult participants into an open-label stabilization period and\nrandomizing 104 participants (90 pediatric, 14 adult) across 77 sites in North\nAmerica and Europe. The objective of this study was to evaluate the\nmaintenance of efficacy of ecopipam in pediatric and adult responders\nutilizing the YGTSS-TTS change from randomization or increased\nTourette-specific care to determine relapse.(5) While this Phase 3 trial\nincluded adult participants, the accepted NDA and resulting indication sought\nby Teva are exclusively for pediatric patients.\n\nAbout Teva\nTeva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into\na leading innovative biopharmaceutical company, enabled by a world-class\ngenerics business. For over 120 years, Teva’s commitment to bettering health\nhas never wavered. From innovating in the fields of neuroscience and\nimmunology to providing complex generic medicines, biosimilars and pharmacy\nbrands worldwide, Teva is dedicated to addressing patients’ needs, now and\nin the future. At Teva, We Are All In For Better Health. To learn more about\nhow, visit www.tevapharm.com.\n\nCautionary Note Regarding Forward-Looking Statements\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995, which are based on\nmanagement’s current beliefs and expectations and are subject to substantial\nrisks and uncertainties, both known and unknown, that could cause Teva’s\nfuture results, performance or achievements to differ significantly from that\nexpressed or implied by such forward-looking statements. All statements other\nthan statements of historical fact are, or may be deemed to be,\nforward-looking statements. In some cases, you can identify these\nforward-looking statements by the use of words such as “should,”\n“expect,” “anticipate,” “developing,” “target,” “may,”\n“expand,” “intend,” “plan,” “believe” and other words and\nterms of similar meaning and expression in connection with any discussion of\nfuture performance. Important factors that could cause or contribute to such\ndifferences include risks and uncertainties relating to: our ability to\nsuccessfully develop, obtain regulatory approval for and commercialize\necopipam; our ability to successfully compete in the marketplace including our\nability to develop and commercialize ecopipam for the treatment of pediatric\npatients with Tourette syndrome; our ability to successfully execute on our\nPivot to Growth strategy, including to expand our innovative and biosimilar\nmedicines pipeline and to profitably commercialize our innovative medicines\nand biosimilar portfolio, whether organically or through business development,\nand to execute on our organizational transformation and to achieve expected\ncost savings; our significant indebtedness, which may limit our ability to\nincur additional indebtedness, engage in additional transactions or make new\ninvestments; and other factors discussed in this press release, in our\nQuarterly Report on Form 10-Q for the second quarter of 2026 and in our Annual\nReport on Form 10-K for the year ended December 31, 2025, including in the\nsections captioned “Risk Factors” and “Cautionary Note Regarding Forward\nLooking Statements.” Forward-looking statements speak only as of the date on\nwhich they are made, and we assume no obligation to update or revise any\nforward-looking statements or other information contained herein, whether as a\nresult of new information, future events or otherwise. You are cautioned not\nto put undue reliance on these forward-looking statements.\n\nReferences:\n1. U.S. Food and Drug Administration (FDA) Approval Records: Haloperidol\n(1969), Pimozide (1984), Aripiprazole (2014); Pringsheim, T., et al. (2019).\nThe pharmacological management of tic disorders: an updated practice\nguideline. Neurology.\n2. CDC | Tourette Syndrome | Data and Statistics on Tourette Syndrome, 2024;\nMayo Clinic | Tourette Syndrome – Diagnosis and treatment, 2025.\n3. Gilbert DL, Dubow JS, Cunniff TM, et al. Ecopipam for Tourette Syndrome: A\nRandomized Trial. Pediatrics. 2023;151(2):e2022059574.\ndoi:10.1542/peds.2022-059574\n4. Gilbert DL, Kim DJB, Miller MM, et al. Safety and Effect of 12-Month\nEcopipam Treatment in Pediatric Patients with Tourette Syndrome. Mov Disord\nClin Pract. 2025;12(8):1157-1166. doi:10.1002/mdc3.70091.\n5. Gilbert DL, Atkinson SD, Kim DJB, et al. Efficacy and Safety of Ecopipam\nfor Tourette Syndrome: A Phase 3 Randomized Clinical Trial. JAMA Neurol.\n2026;83(7):645–653. doi:10.1001/jamaneurol.2026.1431\nTeva Media Inquiries:\nTevaCommunicationsNorthAmerica@tevapharm.com\n\nTeva Investor Relations Inquiries:\nTevaIR@Tevapharm.com"},"type":"article","timestamp":"2026-10-02T12:00:00.396500108Z","server_sent_at_ms":1790942400396},"received_at":"2026-10-02T12:00:00.446Z","source_url":null},"analysis":{"id":"147920","press_release_id":"159302","analysis_json":{"industry":{"label":"Pharmaceuticals","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"Teva presented new ecopipam data at the MDS Congress showing ~70% of pediatric Tourette patients achieved clinically meaningful tic reduction within 8 weeks.\n\nAn interim 18-month open-label analysis showed a 45.6% mean reduction in tic severity scores with no new safety signals, and co-occurring psychiatric conditions did not diminish efficacy.\n\nEcopipam is a first-in-class D1 antagonist already under FDA Priority Review with Orphan Drug designation; if approved it would be the first new Tourette therapy in over a decade.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Supporting congress data de-risks the pending Priority Review decision for ecopipam in pediatric Tourette syndrome."},"keyFigures":{"drugName":"ecopipam","phaseOfTrial":"Phase 2b and Phase 3","customDimensions":{"phase3_n":216,"phase2b_n":153,"ole_interim_n":118,"pooled_post_hoc_n":292,"ygtss_tts responders_8_weeks":"69.8%","median_treatment_exposure_months":14.9,"tic_severity_reduction_18_months":"45.6%"}},"quotedText":"These promising new data for ecopipam reinforce our confidence in its potential in pediatric Tourette syndrome care.","namedEntities":{"people":[{"name":"Eric Hughes, M.D., Ph.D.","role":"EVP Global R&D and Chief Medical Officer, Teva"},{"name":"Donald L. Gilbert, M.D., M.S.","role":"Pediatric Movement Disorders Specialist, Cincinnati Children's Hospital Medical Center"}],"products":["ecopipam"],"companies":[{"name":"Teva Pharmaceutical Industries Ltd.","ticker":"TEVA","relationship":"filer"},{"name":"Cincinnati Children's Hospital Medical Center","relationship":"investigator institution"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Positive new efficacy/safety data for ecopipam presented at a medical congress, supporting an NDA already under FDA Priority Review. Encouraging but incremental -- no new regulatory decision; the binary FDA event remains ahead."},"tickerRelevance":{"others":[],"primary":"TEVA"},"globalImportance":30,"audienceRelevance":35,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"large-cap-pharma","binaryAhead":"FDA Priority Review pending","eventGravity":"supportive-congress-data-not-decision","retailFavoriteBoost":"moderate"}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Teva presented new ecopipam data at the MDS Congress showing ~70% of pediatric Tourette patients achieved clinically meaningful tic reduction within 8 weeks.\n\nAn interim 18-month open-label analysis showed a 45.6% mean reduction in tic severity scores with no new safety signals, and co-occurring psychiatric conditions did not diminish efficacy.\n\nEcopipam is a first-in-class D1 antagonist already under FDA Priority Review with Orphan Drug designation; if approved it would be the first new Tourette therapy in over a decade.","key_figures":{"drugName":"ecopipam","phaseOfTrial":"Phase 2b and Phase 3","customDimensions":{"phase3_n":216,"phase2b_n":153,"ole_interim_n":118,"pooled_post_hoc_n":292,"ygtss_tts responders_8_weeks":"69.8%","median_treatment_exposure_months":14.9,"tic_severity_reduction_18_months":"45.6%"}},"named_entities":{"people":[{"name":"Eric Hughes, M.D., Ph.D.","role":"EVP Global R&D and Chief Medical Officer, Teva"},{"name":"Donald L. Gilbert, M.D., M.S.","role":"Pediatric Movement Disorders Specialist, Cincinnati Children's Hospital Medical Center"}],"products":["ecopipam"],"companies":[{"name":"Teva Pharmaceutical Industries Ltd.","ticker":"TEVA","relationship":"filer"},{"name":"Cincinnati Children's Hospital Medical Center","relationship":"investigator institution"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-02T12:00:05.981Z","global_importance":30,"audience_relevance":35,"importance_components":{"tickerTier":"large-cap-pharma","binaryAhead":"FDA Priority Review pending","eventGravity":"supportive-congress-data-not-decision","retailFavoriteBoost":"moderate"}},"durationMs":5521,"modelName":"glm-5.3-flashx"}}